Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 28, 2026Blood

FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression

View Full Paper
Ask AI
Bookmark
Share

Authors

WZWuju ZhangZYZ L YeXZXuan Zhou

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates that FGF18 neutralization enhances anti-leukemic immunity in AML, indicating a new therapeutic approach.

Key Points

  • This study aims to explore the role of fibroblast-derived FGF18 in acute myeloid leukemia progression and immune dysfunction.
  • Single-cell RNA sequencing of the bone marrow niche to analyze FGF18 expression.
  • Administration of recombinant FGF18 and fibroblast-specific Fgf18 depletion in mouse models.
  • Pooled CRISPR-Cas9 screen to identify FGFR3 signaling in AML cells.
  • Recombinant FGF18 administration accelerated AML progression, while Fgf18 depletion delayed disease and improved survival.
  • FGFR3 genetic loss in AML cells limited leukemic expansion similar to FGF18 deficiency.
  • FGF18 neutralization restored CD8⁺ T cell effector function and synergized with anti-PD-1 therapy to enhance anti-leukemic immunity.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a40bb4561bb0a67205c6d3ehttps://doi.org/10.1182/blood.2026033125
View Full Paper
Ask AI
Bookmark
Share